Treating a tumor like a localized fire and chemotherapy like the extinguisher misses a dangerous reality: the extinguisher is often full of inflammatory kerosene. Funding in oncology is currently obsessed with kill rates while remaining blind to the iatrogenic neutrophil tsunami that follows. When we hit a patient with cisplatin or radiation, we aren't just killing malignant cells—we’re generating a massive systemic reservoir of DNA debris and senescent signals.

This triggers a recruitment of neutrophils that does far more than clear waste. These cells undergo pathological NETosis, casting Neutrophil Extracellular Traps that create a pro-inflammatory mesh across the vascular endothelium. This mesh traps pro-senescent factors, turning a temporary clinical intervention into a permanent, accelerated aging feedback loop.

We celebrate five-year survival rates while ignoring the fact that a patient’s biological age can jump fifteen years during a single treatment course. If a 45-year-old leaves remission with the neutrophil profile and arterial stiffness of a 70-year-old, can we really say we saved them? We’ve essentially traded a rapid malignancy for a slow, expensive systemic collapse.

We need to shift our focus away from the binary "dead vs. alive" metric toward Biological Age Maintenance (BAM). This means funding the development of NET-degrading adjuvants and neutrophil-modulating therapies that allow for tumor clearance without the heavy epigenetic tax.

If oncology grants don’t start requiring longitudinal biological age tracking, we’re just engineering a generation of survivors who are too frail to inhabit the years we’ve given them back. I’m looking for collaborators focused on making NET-degrading DNases a standard post-chemo protocol. We’ve spent decades funding the assassins; it’s time we paid attention to the cleanup crew.